Antengene Pipeline Overview - Antengene is developing a diverse pipeline of Antibody Drug Conjugates (ADCs), Immuno-Oncology (IO) therapies, and treatments for Autoimmune Diseases [16, 102] - The company's "2+1" T Cell Engager (TCE) platform, AnTenGager, is designed with steric hindrance-masking technology to enhance therapeutic effect and safety [20, 109] ATG-022 (Claudin 18.2 ADC) - ATG-022, a Claudin 18.2 ADC, has shown efficacy across various CLDN18.2 expression levels in gastric cancer [20, 32, 48] - In CLDN18.2 moderate to high expressing GC (IHC 2+ > 20%) patients treated with ATG-022 at 2.4 mg/kg, the ORR was 40% (12/30), and the DCR was 90% (27/30) [20] - In CLDN18.2 low and ultra-low expressing GC (IHC 2+ ≤ 20%) patients, an efficacious dose range of 1.8-2.4 mg/kg of ATG-022 resulted in an ORR of 33.3% (6/18) and a DCR of 50% (9/18) [20] - The median progression-free survival (mPFS) in Gastric or GEJ Cancer with Moderate to High CLDN18 2 Expression (IHC 2+, >20%) Treated at 2 4 mg/kg is 6 97 months, with a 6-month progression-free survival (PFS6m) rate of 51 1% [53] - The company is planning to investigate ATG-022 in combination with Pembrolizumab and CAPOX in Advanced / Metastatic Claudin 18 2 Positive Gastric Cancer (1L) [64] - ATG-022 is estimated to have over US$5 billion in peak sales potential [68, 70] ATG-037 (Oral CD73 Small Molecule Inhibitor) - ATG-037, an oral CD73 small molecule inhibitor, has demonstrated efficacy in CPI-resistant Melanoma with an ORR of 36.4% (4/11) and a DCR of 100% (11/11) [20] - In CPI-resistant Non-small Cell Lung Cancer, ATG-037 showed an ORR of 21.4% (3/14) and a DCR of 71.4% (10/14) [20] - The Immuno-oncology (IO) market is estimated to be $140+ billion in 2028 [78] AnTenGager TCE Platform - ATG-201, a CD19 x CD3 TCE, is IND-enabling for B Cell Driven Autoimmune Diseases, demonstrating deep B cell depletion with low CRS [16, 20, 119] - ATG-106 (CDH6 x CD3) is a First-in-Class CDH6 TCE for Ovarian Cancer and Kidney Cancer [17, 103, 132]

Financial Performance - Revenue decreased by 3.1% from HK$392 million to HK$380 million[9, 17] - Profit attributable to equity shareholders decreased by 23.5% from HK$102 million to HK$77 million[9, 17] - Basic & Diluted Earnings per share decreased by 23.9% from HK 10.95 cents to HK 8.33 cents[17] - Gross Profit decreased by 29.6% from HK$147 million to HK$104 million[17] - The board declared an interim dividend of HK 2.50 cents per share[10] Financial Metrics - EBITDA Margin decreased from 77% to 69%[23] - Debt-equity ratio decreased from 14% to 12%[25] Revenue Breakdown - Transponder service accounts for 85.2% of the turnover[19] - Broadcast & Telecom accounts for 0.5% of the turnover[19] - Others accounts for 14.3% of the turnover[19] - Southeast Asia accounts for 65.1% of the turnover[19] - Greater China accounts for 22.6% of the turnover[19, 20] - Others accounts for 12.3% of the turnover[19]

Jiumaojiu International Holdings Limited 九毛九国际控股有限公司 Stock Code 股份代号: 9922 2025年中期业绩发布会 2025 Interim Results Presentation August 2025 Disclaimer This Results Announcement Presentation is for the purpose of your reference only. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects. The information and opinions contained in this document are provided as at the date hereof and ar ...

中国石油化工股份有限公司 S I N O P E C C O R P. Forward-looking Statement This presentation and the presentation materials distributed herein include forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Sinopec Corp. expects or anticipates will or may occur in the future (including but not limited to projections, targets, reserves and other estimates and business plans) are forward-looking statements. Sinopec Corp.'s actual results o ...

Financial Performance - Revenue increased by 3.3% year-over-year to RMB 14,817 million[14] - Net profit was RMB 1,737 million, with a net profit margin of 11.7%[14] - Net operating cash inflow decreased by 11.7% year-over-year to RMB 2,411 million[14] - Gross profit margin decreased by 0.4 percentage points year-over-year to 50.0%[14] - The Board declared an interim dividend of RMB 33.59 cents per ordinary share, with a payout ratio of 50%[14] Channel Performance - Overall channels retail sell-through increased by low-single-digit year-over-year[14] - Offline channel new product sell-through accounted for 84%[14, 21] - Wholesale revenue increased by 5% year-over-year[29] - Direct retail business revenue decreased by 4% year-over-year[34] - Online traffic increased by low-teens[111] Inventory and Working Capital - Channel inventory increased by low-single-digit year-over-year[14] - Company inventory cost amount increased by mid-single-digit year-over-year[103] - The percentage of gross average working capital to revenue was 7.3%[14]

Financial Performance Highlights - The Group's insurance revenue reached RMB 280250 million, a 71% increase[103, 104] - Net profit attributable to equity holders of the company increased by 140% to RMB 26671 million[18, 104] - The Group's consolidated net assets increased by 63% to RMB 3906 billion[20, 43] - Total investment yield (annualized) increased by 09 percentage points to 50%[25, 82, 104] - PICC P&C's combined ratio decreased by 14 percentage points to 948%[27, 59, 104] Segment Performance - PICC P&C's insurance revenue increased by 56% to RMB 249040 million[59, 103, 104] - PICC Life's insurance revenue increased significantly by 325% to RMB 14018 million[70, 103, 104] - PICC Health's insurance revenue increased by 132% to RMB 15603 million[76, 103, 104] Business Growth and Structure Optimization - Group premiums income increased by 64% to RMB 4546 billion[30] - Life & Health premiums income increased by 138%[33] - Total insurance investment assets increased by 72% to RMB 17607 billion[34] Key Initiatives and Focus Areas - The group will focus on strengthening core functions, promoting "Six Reforms", high-quality development, and risk prevention in the second half of 2025[92, 93, 94, 95]

Financial Performance - Sisram Medical's revenue decreased by 1.9% year-over-year to $165.5 million in H1 2025 [9, 71], but excluding North America, revenue grew 7.1% YoY [71] - Gross profit margin decreased by 2.4 percentage points to 60.0% [9, 71], due to product mix and decreased North America revenue [71] - Injectables revenue increased significantly by 218.1% year-over-year [9, 79], driven by geographical expansion and commercialization efforts [80] - Net profit decreased by 31.9% [70] Regional Performance - North America revenue decreased by 15.6% [10, 75] due to market headwinds [75] - APAC revenue increased by 17.6% [10, 75] due to the "Go-Direct" strategy [75] - Europe revenue declined slightly by 0.8% [75], but new EBD platforms saw notable growth [75] - Middle East and Africa revenue decreased by 9.7% [76] due to geopolitical tensions [76] Strategic Initiatives - The company is preparing for the launch of DAXXIFY in mainland China in H2 2025 [13, 45, 86] - The company is expanding global penetration of Alma Harmony, Alma IQ, and Universkin by Alma [86] - The company is driving injectables portfolio Revanesse and Profhilo growth in key markets [86] - The company is developing direct-sales offices in strategic regions [86]

Financial Performance - Core revenue (tissue and hygiene products) decreased by 3.1% to RMB 10.5 billion in 1H2025, compared to RMB 10.8 billion in 1H2024[9] - Profit attributable to shareholders decreased by 2.6% to RMB 1.37 billion in 1H2025, compared to RMB 1.41 billion in 1H2024[9] - Overall revenue slightly decreased by 0.2% to RMB 11,808.232 million in 1H2025, from RMB 11,835.893 million in 1H2024[15] - Basic earnings per share (EPS) decreased by 2.3% to RMB 1.206 in 1H2025, from RMB 1.234 in 1H2024[15] - Interim dividend per share remained unchanged at RMB 0.70[15] Business Segments - Tissue paper revenue increased by 3.2% to RMB 7,173.7 million in 1H2025, compared to RMB 6,950.578 million in 1H2024[18] - Hygiene products revenue decreased by 14.4% to RMB 3,303.839 million in 1H2025, compared to RMB 3,858.570 million in 1H2024[18] - Other revenue increased by 29.6% to RMB 1,330.693 million in 1H2025, compared to RMB 1,026.745 million in 1H2024[18] - Tissue paper sales in e-commerce and new retail channels rose significantly by 15.1%, accounting for nearly 40.9% of overall tissue sales[44] Financial Position - Net cash increased to RMB 6.4 billion in 1H2025, from RMB 5.4 billion in 1H2024[9] - Gearing ratio decreased to 77.5% in 1H2025, from 99.1% in 1H2024[9] - E-commerce and new retail channels sales Up 7.9%, to over RMB 4.06 billion[54] ESG - The company maintained a BBB rating from MSCI ESG Rating[11, 58]

Financial Performance - The company's revenue increased by 18.4% year-over-year, reaching RMB 13318 million in 1H 2025[4] - Net profit increased significantly by 63.1% year-over-year to RMB 876 million in 1H 2025[4] - Basic EPS increased by 65.2% year-over-year to RMB 0.76 in 1H 2025[4] - Operating cash inflow increased by 9.1% year-over-year to RMB 2.89 billion, with free cash flow at RMB 1.86 billion[8] Segment Performance - Acoustics business revenue increased by 1.8% year-over-year to RMB 3.52 billion in 1H 2025, representing 26% of total revenue[13, 12] - Automotive acoustics business revenue increased by 14.2% year-over-year to RMB 1.74 billion in 1H 2025, accounting for 13% of total revenue[18, 17] - Optics business revenue increased by 19.7% year-over-year to RMB 2.65 billion in 1H 2025, contributing 20% of total revenue[22, 21] - Electromagnetic Drives and Precision Mechanics revenue increased by 27.4% year-over-year to RMB 4.63 billion in 1H 2025, making up 35% of total revenue[26, 25] - Sensor and Semiconductor business revenue increased significantly by 56.2% year-over-year to RMB 608 million in 1H 2025, representing 5% of total revenue[35, 34] Optics Gross Margin Improvement - Optics gross margin significantly improved by 5.5 percentage points year-over-year, reaching 10.2% in 1H 2025[22]

東方海外（國際）有限公司 2025 Interim Results | 2025 年中期業績 2 (1) The information/contents herein includes both data provided from Orient Overseas (International) Limited ("OOIL") and its affiliates and data obtained from relevant third-party information provider(s). Such information/contents is purely intended for your reference only and is subject to changes/updates at any time without further notice. (2) The information/contents herein is not a recommendation, an offer to buy, sell or trade in nor solicitation of an ...